Exendin-4 Protects against Hyperglycemia-Induced Cardiomyocyte Pyroptosis via the AMPK-TXNIP Pathway
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
Diabetic cardiomyopathy is a common cardiac condition in patients with diabetes mellitus, which results in cardiac hypertrophy and subsequent heart failure. Chronic inflammation in the diabetic heart results in loss of cardiomyocytes and subsequentially cardiac dysfunction. Accumulated evidence implicated pyroptosis as a vital contributor to the hyperglycemia-induced cardiac inflammatory response. Exendin-4, a GLP analog, promotes survival of cardiomyocytes in cardiovascular diseases, including diabetic cardiomyopathy. However, the role of Exendin-4 in cardiac pyroptosis remains to be elucidated. Our study revealed that Exendin-4 treatment protected against heart remolding and dysfunction and attenuated cardiac inflammation in high-fat diet-fed rats. The activity of caspase-1 and production of pyroptotic cytokines were significantly inhibited by Exendin-4 treatment in the diabetic heart and in high glucose-treated cardiomyocytes as well. In an effort to understand the signaling mechanisms underlying the antipyroptotic property of Exendin-4, we found that blockade of AMPK, an oxidative stress sensor, activity diminished the antipyroptotic property of Exendin-4. Phosphorylation of AMPK resulted in degeneration of TXNIP that promoted the activation of the NLRP3 inflammasome. Exendin-4 treatment decreased the protein level of TXNIP. Moreover, RNA silencing of TXNIP mimicked the antipyroptotic actions of Exendin-4. These findings promoted us to propose a new signaling pathway mediating cardioprotective effect of Exendin-4 under hyperglycemic conditions: Exendin-4 → ROS↓ → pAMPK↑ → TXNIP↓ → caspase-1↓ → IL-1 β and IL-18↓ → pyroptosis↓. In general, our study identified Exendin-4 as a pyroptotic inhibitor protecting against hyperglycemia-induced cardiomyocyte pyroptosis via the AMPK-TXNIP pathway.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Beyond improving the metabolic profile, GLP-1 RAs have been shown to significantly reduce serum levels of CRP [80,134,135,136], IL-6 [137] and TNF-α [136].”
From GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives (2023) · cites this paper as [137]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A role for mitochondria in nlrp3 inflammasome activation
Zhou, R., Yazdi, A. S., Menu, P., & Tschopp, J. (2011) · Nature · doi:10.1038/nature09663 · Cited by 5,602
Inflammatory responses and inflammation-associated diseases in organs
Chen, L., Deng, H., Cui, H., Fang, J., Zuo, Z., Deng, J., Li, Y., Wang, X., & Zhao, L. (2018) · Oncotarget · doi:10.18632/oncotarget.23208 · Cited by 5,143 · cited 1×
“As shown in previous studies [3, 6, 35, 36], diabetic cardiac tissues express increased level of multiple proinflammatory cytokines promoting progression of myocardial 0.”
BackgroundPyroptosis: host cell death and inflammation
Bergsbaken, T., Fink, S. L., & Cookson, B. T. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2070 · Cited by 3,183 · cited 1×
“Pyroptosis, the proinflammatory programmed cell death, is mechanistically different from necrosis and apoptosis [10].”
BackgroundIL-10 inhibits cytokine production by activated macrophages
Fiorentino, D. F., Zlotnik, A., Mosmann, T. R., Howard, M., & O’Garra, A. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.147.11.3815 · Cited by 2,888
Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity
Henao-Mejia, J., Elinav, E., Jin, C., Hao, L., Mehal, W. Z., Strowig, T., Thaiss, C. A., Kau, A. L., Eisenbarth, S. C., Jurczak, M. J., et al. (2012) · Nature · doi:10.1038/nature10809 · Cited by 2,435
Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes
Holman, R. R., Bethel, M. A., Mentz, R. J., Thompson, V. P., Lokhnygina, Y., Buse, J. B., Chan, J. C., Choi, J., Gustavson, S. M., Iqbal, N., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612917 · Cited by 2,162 · cited 1×
“Exendin-4 has been characterized by cardioprotective effects on cardiovascular diseases, including DCM, in human being [31].”
BackgroundFranchi, L., Eigenbrod, T., Muñoz-Planillo, R., & Nuñez, G. (2009) · Nature Immunology · doi:10.1038/ni.1703 · Cited by 1,834 · cited 2×
“The inflammasome is characterized as a molecular dock recruiting procaspase-1 and facilitates its autoactivation [13].”
BackgroundDiabetic Cardiomyopathy: An Update of Mechanisms Contributing to This Clinical Entity
Jia, G., Hill, M. A., & Sowers, J. R. (2018) · Circulation Research · doi:10.1161/circresaha.117.311586 · Cited by 1,807 · cited 15×
“Pyroptosis is a great contributor to cardiac inflammation in DCM [21].”
BackgroundInfluentialFink, S. L., & Cookson, B. T. (2006) · Cellular Microbiology · doi:10.1111/j.1462-5822.2006.00751.x · Cited by 1,110 · cited 2×
“Pyroptosis results in the release of cytokines that activate proinflammatory immune cells [11, 12].”
BackgroundBan, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S.-S., Drucker, D. J., & Husain, M. (2008) · Circulation · doi:10.1161/circulationaha.107.739938 · Cited by 1,057 · cited 13×
“Pyroptosis is a great contributor to cardiac inflammation in DCM [21].”
BackgroundInfluentialWinzell, M. S., & Ahrén, B. (2004) · Diabetes · doi:10.2337/diabetes.53.suppl_3.s215 · Cited by 1,026 · cited 1×
“A high-fat diet(HFD-) fed mouse model is robust to mimic metabolic abnormalities in human diabetic patients, including obesity, hyperglycemia, and complications of diabetes [20].”
BackgroundPro‐ and anti‐inflammatory cytokine balance in strenuous exercise in humans
Ostrowski, K., Rohde, T., Asp, S., Schjerling, P., & Pedersen, B. K. (1999) · The Journal of Physiology · doi:10.1111/j.1469-7793.1999.287ad.x · Cited by 1,014
Diabetic cardiomyopathy: a hyperglycaemia- and insulin-resistance-induced heart disease
Jia, G., Whaley-Connell, A., & Sowers, J. R. (2018) · Diabetologia · doi:10.1007/s00125-017-4390-4 · Cited by 868 · cited 14×
“Pyroptosis is a great contributor to cardiac inflammation in DCM [21].”
BackgroundInfluentialAMPK-Dependent Degradation of TXNIP upon Energy Stress Leads to Enhanced Glucose Uptake via GLUT1
Wu, N., Zheng, B., Shaywitz, A., Dagon, Y., Tower, C., Bellinger, G., Shen, C.-H., Wen, J., Asara, J., McGraw, T. E., et al. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.01.035 · Cited by 665 · cited 2×
“Activated AMPK degenerates TXNIP to manipulate the activity of the NLRP3 inflammasome [29].”
BackgroundRole of pyroptosis in cardiovascular disease
Zhaolin, Z., Guohua, L., Shiyuan, W., & Zuo, W. (2019) · Cell Proliferation · doi:10.1111/cpr.12563 · Cited by 493 · cited 14×
“Pyroptosis is a great contributor to cardiac inflammation in DCM [21].”
BackgroundInfluentialTimmers, L., Henriques, J. P. S., de Kleijn, D. P. V., DeVries, J. H., Kemperman, H., Steendijk, P., Verlaan, C. W. J., Kerver, M., Piek, J. J., Doevendans, P. A., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.10.033 · Cited by 470 · cited 1×
“Pretreatment of Exendin-4 also reduces the infarct area in the rat heart after ischemia reperfusion [19].”
BackgroundKrishnamurthy, P., Rajasingh, J., Lambers, E., Qin, G., Losordo, D. W., & Kishore, R. (2009) · Circulation Research · doi:10.1161/circresaha.108.188243 · Cited by 420
NLRP3 Gene Silencing Ameliorates Diabetic Cardiomyopathy in a Type 2 Diabetes Rat Model
Luo, B., Li, B., Wang, W., Liu, X., Xia, Y., Zhang, C., Zhang, M., Zhang, Y., & An, F. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104771 · Cited by 408 · cited 3×
“pyroptosis and myocardial inflammation via activating the NLRP3 inflammasome [5, 7].”
BackgroundMungai, P. T., Waypa, G. B., Jairaman, A., Prakriya, M., Dokic, D., Ball, M. K., & Schumacker, P. T. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.05124-11 · Cited by 385 · cited 1×
“Meanwhile, the activation of AMPK is driven by oxidative stress via ROS-dependent phosphorylation [30].”
BackgroundLiu, Y., Lian, K., Zhang, L., Wang, R., Yi, F., Gao, C., Xin, C., Zhu, D., Li, Y., Yan, W., et al. (2014) · Basic Research in Cardiology · doi:10.1007/s00395-014-0415-z · Cited by 321 · cited 1×
“In this study, the protein level of inflammasome components, NLRP3 and ASC, was not affected by Exendin-4-treated hyperglycemia cultured cardiomyocytes, while the upstream activator of inflammasome, TXNIP, was downregulated significantly [22, 24].”
BackgroundLi, X., Du, N., Zhang, Q., Li, J., Chen, X., Liu, X., Hu, Y., Qin, W., Shen, N., Xu, C., et al. (2014) · Cell Death & Disease · doi:10.1038/cddis.2014.430 · Cited by 315 · cited 1×
“pyroptosis and myocardial inflammation via activating the NLRP3 inflammasome [5, 7].”
BackgroundSilencing long non-coding RNA Kcnq1ot1 alleviates pyroptosis and fibrosis in diabetic cardiomyopathy
Yang, F., Qin, Y., Lv, J., Wang, Y., Che, H., Chen, X., Jiang, Y., Li, A., Sun, X., Yue, E., et al. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-1029-4 · Cited by 273
Caspase-1-dependent processing of pro-interleukin-1β is cytosolic and precedes cell death
Brough, D., & Rothwell, N. J. (2007) · Journal of Cell Science · doi:10.1242/jcs.03377 · Cited by 265 · cited 3×
“Meanwhile, IL-1β is a direct target of caspase-1, the pyroptotic-specific proteinase caspase [11].”
BackgroundCardiovascular risk assessment in patients with diabetes
Bertoluci, M. C., & Rocha, V. Z. (2017) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-017-0225-1 · Cited by 255 · cited 1×
“Patients with diabetes suffer from cardiovascular diseases 2 to 4 times likely than individuals without diabetes [1].”
BackgroundFrati, G., Schirone, L., Chimenti, I., Yee, D., Biondi-Zoccai, G., Volpe, M., & Sciarretta, S. (2017) · Cardiovascular Research · doi:10.1093/cvr/cvx011 · Cited by 244 · cited 2×
“As shown in previous studies [3, 6, 35, 36], diabetic cardiac tissues express increased level of multiple proinflammatory cytokines promoting progression of myocardial 0.”
BackgroundNLRP3 Inflammasome as a Molecular Marker in Diabetic Cardiomyopathy
Luo, B., Huang, F., Liu, Y., Liang, Y., Wei, Z., Ke, H., Zeng, Z., Huang, W., & He, Y. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00519 · Cited by 213 · cited 2×
“As shown in previous studies [3, 6, 35, 36], diabetic cardiac tissues express increased level of multiple proinflammatory cytokines promoting progression of myocardial 0.”
BackgroundPhysiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes
Gautier, J.-F., Choukem, S.-P., & Girard, J. (2008) · Diabetes & Metabolism · doi:10.1016/s1262-3636(08)73397-4 · Cited by 183
Chen, W., Zhao, M., Zhao, S., Lu, Q., Ni, L., Zou, C., Lu, L., Xu, X., Guan, H., Zheng, Z., et al. (2017) · Inflammation Research · doi:10.1007/s00011-016-1002-6 · Cited by 178 · cited 1×
“In this study, the protein level of inflammasome components, NLRP3 and ASC, was not affected by Exendin-4-treated hyperglycemia cultured cardiomyocytes, while the upstream activator of inflammasome, TXNIP, was downregulated significantly [22, 24].”
BackgroundNLRP3: A Novel Mediator in Cardiovascular Disease
Zhou, W., Chen, C., Chen, Z., Liu, L., Jiang, J., Wu, Z., Zhao, M., & Chen, Y. (2018) · Journal of Immunology Research · doi:10.1155/2018/5702103 · Cited by 172 · cited 14×
“Pyroptosis is a great contributor to cardiac inflammation in DCM [21].”
BackgroundInfluentialSelf-citationLncRNA KCNQ1OT1 Mediates Pyroptosis in Diabetic Cardiomyopathy
Yang, F., Qin, Y., Wang, Y., Li, A., Lv, J., Sun, X., Che, H., Han, T., Meng, S., Bai, Y., et al. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000494576 · Cited by 166
Anguera, I., Miranda‐Guardiola, F., Bosch, X., Filella, X., Sitges, M., Marı́n, J. L., Betriu, A., & Sanz, G. (2002) · American Heart Journal · doi:10.1067/mhj.2002.124831 · Cited by 118 · cited 1×
“The increased level of IL-10 has also been observed associated with inflammation in various cardiovascular diseases [37, 38].”
BackgroundTXNIP shuttling: missing link between oxidative stress and inflammasome activation
Lane, T., Flam, B., Lockey, R., & Kolliputi, N. (2013) · Frontiers in Physiology · doi:10.3389/fphys.2013.00050 · Cited by 108 · cited 1×
“As a link between oxidative stress and cardiac inflammation in various cardiovascular diseases [26], TNXIP is a potential regulator involved in the antipyroptotic property of Exendin-4 in high glucose-induced cardiomyocytes.”
BackgroundMizia‐Stec, K., sior, Z. G., Zahorska‐Markiewicz, B., Janowska, J., Szulc, A., Jastrzebska-Maj, E., & Kobielusz‐Gembala, I. (2003) · Coronary Artery Disease · doi:10.1097/00019501-200309000-00003 · Cited by 95
Dhingra, S., Bagchi, A. K., Lüdke, A., Sharma, A. K., & Singal, P. K. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025009 · Cited by 70 · cited 1×
“Therefore, we also proposed that upregulation of IL-10 as a protective mechanism in the HFD-induced diabetic heart attenuates immune response and facilitates cell survival [43].”
BackgroundAMPK is associated with the beneficial effects of antidiabetic agents on cardiovascular diseases
Lu, Q., Li, X., Liu, J., Sun, X., Rousselle, T., Ren, D., Tong, N., & Li, J. (2019) · Bioscience Reports · doi:10.1042/bsr20181995 · Cited by 69 · cited 14×
“Pyroptosis is a great contributor to cardiac inflammation in DCM [21].”
BackgroundInfluentialYu, W., Zha, W., & Ren, J. T. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/5396806 · Cited by 61
Chang, G., Zhang, D., Liu, J., Zhang, P., Ye, L., Lu, K., Duan, Q., Zheng, A., & Qin, S. (2014) · Experimental Biology and Medicine · doi:10.1177/1535370214522177 · Cited by 59
Ding, W., Chang, W.-G., Guo, X.-C., Liu, Y., Xiao, D.-D., Ding, D., Wang, J.-X., & Zhang, X.-J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00202 · Cited by 50 · cited 1×
“In diabetic rodent models, Exendin-4 treatment improved cardiac function and glucose uptake [18].”
BackgroundChang, G., Liu, J., Qin, S., Jiang, Y., Zhang, P., Yu, H., Lu, K., Zhang, N., Cao, L., Wang, Y., et al. (2017) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2017.3318 · Cited by 48
Meng, X., Zheng, M., Yu, M., Bai, W., Zuo, L., Bu, X., Liu, Y. F., Xia, L., Hu, J. R., Liu, L., et al. (2019) · Journal of Biological Engineering · doi:10.1186/s13036-019-0163-6 · Cited by 47
Diabetes and the Heart: Is There Objective Evidence of a Human Diabetic Cardiomyopathy?
Litwin, S. E. (2013) · Diabetes · doi:10.2337/db13-0683 · Cited by 42
Exenatide Activates the APPL1-AMPK-PPARαAxis to Prevent Diabetic Cardiomyocyte Apoptosis
XiaoTian, L., Wu, Q., XiaGuang, G., WuQuan, D., Chen, B., & ZiWen, L. (2015) · Journal of Diabetes Research · doi:10.1155/2016/4219735 · Cited by 27 · cited 13×
“Pyroptosis is a great contributor to cardiac inflammation in DCM [21].”
BackgroundInfluentialThe NLRP3 Inflammasome and Diabetic Cardiomyopathy
Singh, L. P. (2013) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-013-6501-x · Cited by 26
Exenatide, a GLP-1 agonist in the treatment of Type 2 diabetes
Sennik, D., Ahmed, F. W., & Russell-Jones, D. (2012) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.11.79 · Cited by 10 · cited 1×
“Exendin-4, a GLP analog, has a longer half-life than GLP-1 through evading clearance by dipeptidyl peptidase IV (DPP-4) [17].”
Background
Cited by
Entezari, M., Hashemi, D., Taheriazam, A., Zabolian, A., Mohammadi, S., Fakhri, F., Hashemi, M., Hushmandi, K., Ashrafizadeh, M., Zarrabi, A., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112563 · Cited by 400
RetractedGLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
Ma, X., Liu, Z., Ilyas, I., Little, P. J., Kamato, D., Sahebka, A., Chen, Z., Luo, S., Zheng, X., Weng, J., et al. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.59965 · Cited by 299
“GLP-1RAs have the potential to inhibit cardiac inflammation via retarding the production of pyroptotic cytokines, caspase-1 and the AMPK-thioredoxin interacting protein (TXNIP) pathway in high-fat diet-fed rats [80].”
BackgroundNevola, R., Epifani, R., Imbriani, S., Tortorella, G., Aprea, C., Galiero, R., Rinaldi, L., Marfella, R., & Sasso, F. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021703 · Cited by 286
“Beyond improving the metabolic profile, GLP-1 RAs have been shown to significantly reduce serum levels of CRP [80,134–136], IL-6 [137] and TNF-α [136].”
BackgroundSong, S., Guo, R., Mehmood, A., Zhang, L., Yin, B., Yuan, C., Zhang, H., Guo, L., & Li, B. (2022) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13791 · Cited by 109
Preliminary evidence for the presence of multiple forms of cell death in diabetes cardiomyopathy
Wei, J., Zhao, Y., Liang, H., Du, W., & Wang, L. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.08.026 · Cited by 111
Metadata
- Authors
- Wei, H., Bu, R., Yang, Q., Jia, J., Li, T., Wang, Q., & Chen, Y.
- Affiliations
- Harbin Medical University (CN)
- Peking University Shenzhen Hospital (CN)
- Corresponding author
- Chen, Yanjun
- Venue
- Journal of Diabetes Research
- Publisher
- Wiley
- Published
- 2019-12-09
- Volume
- 2019
- Pages
- 1-13
- ISSN
- 2314-6745 (ISSN-L)
- 2314-6753
- PMC
- PMC6925927
- OpenAlex
- W2993303703
- Cited by
- 91
- References
- 44
- Citations by year
- 2026: 4 · 2025: 14 · 2024: 17 · 2023: 12 · 2022: 24 · 2021: 15 · 2020: 5
- FWCI
- 3.64
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Journal of Diabetes Research (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Project of Health Commission of Heilongjiang Province (2018068)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- exendin-4, cardiomyocyte pyroptosis, diabetic cardiomyopathy, hyperglycemia, AMPK, TXNIP, NLRP3 inflammasome, caspase-1, IL-1β, IL-18, oxidative stress, GLP-1 receptor agonists, cardiac inflammation, heart failure
- MeSH terms
- Pyroptosis, NLR Family, Pyrin Domain-Containing 3 Protein, Exenatide, Animals, Blood Glucose, Carrier Proteins, Cells, Cultured, Diabetes Mellitus, Experimental, Diabetes Mellitus, Type 2, Hypoglycemic Agents, Mice, Inbred C57BL, Phosphorylation, Thioredoxins, Signal Transduction, Biomarkers, Reactive Oxygen Species, Caspase 1, Interleukin-18, Myocytes, Cardiac, Interleukin-1beta, Incretins, AMP-Activated Protein Kinases, Diabetic Cardiomyopathies, Proteolysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.